share_log

Biodexa Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ionic Ventures, LLC(4.9%),Ionic Management, LLC(4.9%), etc.

SEC announcement ·  Feb 15 09:48
Summary by Futu AI
Biodexa Pharmaceuticals PLC, a company with principal executive offices in Cardiff, United Kingdom, has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The amendment, known as Schedule 13G/A, indicates that several reporting persons, including Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, have collectively ceased to be the beneficial owners of more than five percent of the company's outstanding American Depositary Shares (ADSs). The filing, which serves as an exit filing for the reporting persons, updates their beneficial ownership information and amends previous disclosures. The ADSs in question represent 400 ordinary shares each, with a nominal value of £0.001 per share. The reporting persons had shared voting...Show More
Biodexa Pharmaceuticals PLC, a company with principal executive offices in Cardiff, United Kingdom, has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The amendment, known as Schedule 13G/A, indicates that several reporting persons, including Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, have collectively ceased to be the beneficial owners of more than five percent of the company's outstanding American Depositary Shares (ADSs). The filing, which serves as an exit filing for the reporting persons, updates their beneficial ownership information and amends previous disclosures. The ADSs in question represent 400 ordinary shares each, with a nominal value of £0.001 per share. The reporting persons had shared voting and dispositive power over 135,532 ADSs, which equates to a 4.9% ownership of the class. The amendment also details the limitations on the exercise of certain Series D, E, and F purchase warrants due to beneficial ownership blockers set at 9.99% and 4.99%. The reporting persons' principal business address is in San Francisco, California, and they have entered into a Joint Filing Agreement to file this and any subsequent amendments jointly.

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.